Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer
Copyright © 2023 Elsevier B.V. All rights reserved..
Lung cancer ranks as the second most commonly diagnosed cancer in both men and women worldwide. Despite the availability of diverse diagnostic and treatment strategies, it remains the leading cause of cancer-related deaths globally. The current treatment approaches for lung cancer involve the utilization of first generation (e.g., erlotinib, gefitinib) and second generation (e.g., afatinib) tyrosine kinase inhibitors (TKIs). These TKIs exert their effects by inhibiting a crucial enzyme called tyrosine kinase, which is responsible for cell survival signaling. However, their clinical effectiveness is hindered by limited solubility and oral bioavailability. Nanotechnology has emerged as a significant application in modern cancer therapy. Nanoparticle-based drug delivery systems, including lipid, polymeric, hybrid, inorganic, dendrimer, and micellar nanoparticles, have been designed to enhance the bioavailability, stability, and retention of these drugs within the targeted lung area. Furthermore, these nanoparticle-based delivery systems offer several advantages, such as increased therapeutic efficacy and reduced side effects and toxicity. This review focuses on the recent advancements in drug delivery systems for some of the most important TKIs, shedding light on their potential in improving lung cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:650 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 650(2024) vom: 25. Jan., Seite 123703 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Korucu Aktas, Pelinsu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 08.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2023.123703 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365829676 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365829676 | ||
| 003 | DE-627 | ||
| 005 | 20240114232056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2023.123703 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1252.xml |
| 035 | |a (DE-627)NLM365829676 | ||
| 035 | |a (NLM)38092263 | ||
| 035 | |a (PII)S0378-5173(23)01125-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Korucu Aktas, Pelinsu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Lung cancer ranks as the second most commonly diagnosed cancer in both men and women worldwide. Despite the availability of diverse diagnostic and treatment strategies, it remains the leading cause of cancer-related deaths globally. The current treatment approaches for lung cancer involve the utilization of first generation (e.g., erlotinib, gefitinib) and second generation (e.g., afatinib) tyrosine kinase inhibitors (TKIs). These TKIs exert their effects by inhibiting a crucial enzyme called tyrosine kinase, which is responsible for cell survival signaling. However, their clinical effectiveness is hindered by limited solubility and oral bioavailability. Nanotechnology has emerged as a significant application in modern cancer therapy. Nanoparticle-based drug delivery systems, including lipid, polymeric, hybrid, inorganic, dendrimer, and micellar nanoparticles, have been designed to enhance the bioavailability, stability, and retention of these drugs within the targeted lung area. Furthermore, these nanoparticle-based delivery systems offer several advantages, such as increased therapeutic efficacy and reduced side effects and toxicity. This review focuses on the recent advancements in drug delivery systems for some of the most important TKIs, shedding light on their potential in improving lung cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a Lipid and polymer-based nanocarriers | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a Nanoparticles | |
| 650 | 4 | |a Tyrosine kinase | |
| 650 | 4 | |a Tyrosine kinase inhibitors | |
| 650 | 7 | |a Tyrosine Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Baysal, Ipek |e verfasserin |4 aut | |
| 700 | 1 | |a Yabanoglu-Ciftci, Samiye |e verfasserin |4 aut | |
| 700 | 1 | |a Lamprecht, Alf |e verfasserin |4 aut | |
| 700 | 1 | |a Arica, Betul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 650(2024) vom: 25. Jan., Seite 123703 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:650 |g year:2024 |g day:25 |g month:01 |g pages:123703 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2023.123703 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 650 |j 2024 |b 25 |c 01 |h 123703 | ||